A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

Inclusion Criteria: * Be premenopausal, between 18 and 39 years of age * Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result comply with diagnosis of hypogonadotropic hypogonadism during screening procedure * Have discontinued gonadotropins, gonadotropin-releasing hormone (GnRH) (gonadotropin naïve), or estrogen progesterone replacement therapy at least one month before the screening procedure * Have a negative progestin challenge test performed during screening * Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 months before initiation of treatment: * Follicular stimulating hormone (FSH): \< 5 international units/liter (IU/L) * Luteinizing hormone (LH): \< 1.2 IU/L * Oestradiol (E2): \< 60 picogram/milliliter (pg/mL) (\<220 picomolar/liter \[pmol/L\]) * Prolactin (PRL): \< 44.3 nanogram/milliliter (ng/mL) (\< 1040 milli-international units/liter \[mIU/L\]) * Thyrotrophin-stimulating hormone (TSH): \< 6.5 micro-international units (uIU/mL) * Free Thyroxine (T4): 0.8-1.8 nanogram/deciliter (ng/dL) (11-24 pmol/L) * Triiodothyronine (T3): \< 1.0 ng/mL (\< 3.5 nanomolar/liter \[nmol/L\]) * Have an endovaginal pelvic ultrasound scan showing (i) no ovarian tumor and cyst \< 2 centimeters (cm); (ii) no clinically significant uterine abnormality, and (iii) \< 13 mm small follicles (mean diameter \< 10 mm) on the largest section through each ovary * Have a normal cervical pap smear within 6 months of the initial visit * Have a body mass index (BMI) between 18.4 and 31.4 kilogram/meter square (kg/m\^2) * Be willing and able to comply with the protocol for the duration of the study * Have given written informed consent prior to any study related procedure Exclusion Criteria: * Ongoing pregnancy * Any chronic systemic disease * Hypersensitive to study drug and control drug * History of severe ovarian hyperstimulation syndrome * Abnormal gynecological bleeding of undetermined origin * Previous or current hormone dependent tumor * Known active substance abuse or eating disorder * Known central nervous system (CNS) lesions: In cases where hypogonadotropic hypogonadism (HH) is secondary to a CNS lesion or its treatment, the subject will not be eligible without consulting Serono's Medical Director * Exercise program exceeding 10 hours per week * Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (for example, neuroleptics, dopamine antagonists) * There is any abnormality, decided by investigators, which might produce effect on the absorption, distribution and excretion of investigational drug